175 related articles for article (PubMed ID: 38001638)
1. ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma.
Zhang L; Zheng Y; Chien W; Ziman B; Billet S; Koeffler HP; Lin DC; Bhowmick NA
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001638
[TBL] [Abstract][Full Text] [Related]
2. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.
Streppel MM; Lata S; DelaBastide M; Montgomery EA; Wang JS; Canto MI; Macgregor-Das AM; Pai S; Morsink FH; Offerhaus GJ; Antoniou E; Maitra A; McCombie WR
Oncogene; 2014 Jan; 33(3):347-57. PubMed ID: 23318448
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors.
Wang L; Yang L; Wang C; Zhao W; Ju Z; Zhang W; Shen J; Peng Y; An C; Luu YT; Song S; Yap TA; Ajani JA; Mills GB; Shen X; Peng G
J Clin Invest; 2020 Nov; 130(11):5951-5966. PubMed ID: 33016929
[TBL] [Abstract][Full Text] [Related]
5. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
6. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
Villatoro TM; Ma C; Pai RK
Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
[TBL] [Abstract][Full Text] [Related]
7. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
8. Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex.
Tsuruta S; Kohashi K; Yamada Y; Fujiwara M; Koga Y; Ihara E; Ogawa Y; Oki E; Nakamura M; Oda Y
Cancer Sci; 2020 Mar; 111(3):1008-1019. PubMed ID: 31922331
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.
Fukumoto T; Fatkhutdinov N; Zundell JA; Tcyganov EN; Nacarelli T; Karakashev S; Wu S; Liu Q; Gabrilovich DI; Zhang R
Cancer Res; 2019 Nov; 79(21):5482-5489. PubMed ID: 31311810
[No Abstract] [Full Text] [Related]
10. Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
Takahashi K; Takenaka M; Okamoto A; Bowtell DDL; Kohno T
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917230
[TBL] [Abstract][Full Text] [Related]
11. Morphological Features and Prognostic Significance of ARID1A-Deficient Esophageal Adenocarcinomas.
Drage MG; Tippayawong M; Agoston AT; Zheng Y; Bueno R; Hornick JL; Odze RD; Srivastava A
Arch Pathol Lab Med; 2017 Jul; 141(7):970-977. PubMed ID: 28440661
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
[TBL] [Abstract][Full Text] [Related]
13. A study of the immune infiltrate and patient outcomes in esophageal cancer.
Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J
Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666
[TBL] [Abstract][Full Text] [Related]
14. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
[TBL] [Abstract][Full Text] [Related]
15. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract][Full Text] [Related]
16. ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications.
Xu W; Dong H; Ru G; Zhao M
Diagn Pathol; 2022 Feb; 17(1):22. PubMed ID: 35125107
[TBL] [Abstract][Full Text] [Related]
17. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract][Full Text] [Related]
18. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
19. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
20. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
